Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
NCT03275311 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40000
Last updated 2025-04-25
Summary
The Epidemiological Strategy and Medical Economic (ESME) Breast cancer Database is a multicenter real life database using a retrospective data collection process across 18 French comprehensive cancer centers (FCCC) spread over 20 sites. This database compiles data from patient's electronic medical records (EMR).
Conditions
Sponsors & Collaborators
-
Roche Pharma AG
collaborator INDUSTRY -
Pierre Fabre Laboratories
collaborator INDUSTRY - collaborator INDUSTRY
- collaborator INDUSTRY
- collaborator INDUSTRY
-
Eisai Inc.
collaborator INDUSTRY - collaborator INDUSTRY
- collaborator INDUSTRY
- collaborator INDUSTRY
-
Seagen Inc.
collaborator INDUSTRY -
UNICANCER
lead OTHER
Principal Investigators
-
Lise Bosquet, MsC · UNICANCER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-07-31
- Primary Completion
- 2026-03-31
- Completion
- 2026-12-31
Countries
- France
Study Locations
More Related Trials
-
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
NCT01373710 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
NCT06305702 ·Status: COMPLETED
-
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
NCT01975142 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
NCT02819882 ·Status: RECRUITING
-
Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)
NCT01956552 ·Status: TERMINATED ·Phase: NA
-
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
NCT01615068 ·Status: COMPLETED
-
Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer
NCT03979911 ·Status: UNKNOWN
-
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
NCT03355157 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
NCT02860585 ·Status: COMPLETED
-
Metabolomics Explores Biomarkers for Metastatic Breast Cancer
NCT04302415 ·Status: UNKNOWN
-
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
NCT01332981 ·Status: COMPLETED
-
Patients With Brain Metastases From HER2-positive Breast Cancer
NCT02135159 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer
NCT02089100 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
NCT01038804 ·Status: COMPLETED ·Phase: PHASE2
-
Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT00896376 ·Status: COMPLETED ·Phase: NA
-
Epidemiology and Management of Metastatic Breast Cancer
NCT01711502 ·Status: COMPLETED
-
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
NCT01513083 ·Status: COMPLETED ·Phase: PHASE1
-
Rapid Medical Donation Programme for Breast Cancer
NCT02126800 ·Status: UNKNOWN
-
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
NCT04258163 ·Status: COMPLETED
-
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT00829166 ·Status: COMPLETED ·Phase: PHASE3
-
Thero2-01S22 in HER2-positive Breast Cancer
NCT05698186 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Study of Impact of Routine "Clinical Cancer Department/Supportive Care Department" Consultation on the Prescription of an Additional Line of Chemotherapy
NCT00905281 ·Status: COMPLETED ·Phase: NA
-
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
NCT01597414 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
NCT01702571 ·Status: COMPLETED ·Phase: PHASE3